Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–17 of 17 results
Advanced filters: Author: Brad H. Rovin Clear advanced filters

  • Lupus nephritis is an autoimmune-mediated glomerulonephritis and a serious complication of systemic lupus erythematosus. In this Primer, Parodis and colleagues describe the epidemiology and pathophysiology of this disease, discuss current diagnosis and management, and highlight the effects on patient quality of life as well as future areas of research.

    • Ioannis Parodis
    • Brad H. Rovin
    • Chandra Mohan
    Reviews
    Nature Reviews Disease Primers
    Volume: 11, P: 1-19

  • The development of novel immunotherapies has improved treatment options for several immune-mediated diseases; however, outcomes for patients with immune-mediated kidney disease remain poor. In this Review, Hans-Joachim Anders, David Jayne and Brad Rovin suggest that this lack of progress relates to shortcomings in the approaches used to identify targets and measure outcomes. They discuss seven hurdles to the validation of therapeutic targets in immune-mediated kidney diseases and describe how these hurdles can be overcome to appropriately assess and introduce immunologic therapies for immune-mediated kidney disease.

    • Hans-Joachim Anders
    • David R. W. Jayne
    • Brad H. Rovin
    Reviews
    Nature Reviews Nephrology
    Volume: 12, P: 205-216

  • Comprehensive integration of gene expression with epigenetic features is needed to understand the transition of kidney cells from health to injury. Here, the authors integrate dual single nucleus RNA expression and chromatin accessibility, DNA methylation, and histone modifications to decipher the chromatin landscape of the kidney in reference and adaptive injury cell states, identifying a transcription factor network of ELF3, KLF6, and KLF10 which regulates adaptive repair and maladaptive failed repair.

    • Debora L. Gisch
    • Michelle Brennan
    • Michael T. Eadon
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-21

  • Several management guidelines for lupus nephritis have been published this year. All of the guidelines provide clear and consistent recommendations, but although evidence-based, many of the recommendations are not supported by high-quality clinical data. The guidelines reveal these evidence gaps and are thus an important roadmap for future lupus nephritis clinical research.

    • Brad H. Rovin
    News & Views
    Nature Reviews Nephrology
    Volume: 8, P: 620-621

  • Although ALMS, the largest prospective, randomized, controlled study comparing mycophenolate mofetil to intravenous cyclophosphamide for the initial treatment of severe lupus nephritis, failed to achieve its primary end point of mycophenolate superiority, mycophenolate plus corticosteroids has become the accepted standard of care. Are we really beyond cyclophosphamide for severe lupus nephritis?

    • Brad H. Rovin
    News & Views
    Nature Reviews Nephrology
    Volume: 5, P: 492-494

  • Despite aggressive therapy, lupus nephritis (LN) remains an important predictor of morbidity in patients with systemic lupus erythematosus. Clinical trials of novel drugs have not improved LN outcomes; however, re-analysis of well-characterized cohorts has identified surrogate end points of long-term renal survival, which will facilitate testing and qualification of novel treatments.

    • Brad H. Rovin
    • Isabelle Ayoub
    News & Views
    Nature Reviews Nephrology
    Volume: 11, P: 389-390

  • The US National High Blood Pressure Education Program currently advocates diuretics as first-line treatment for all patients with hypertension, based mainly on the findings of ALLHAT. This Viewpoint identifies several flaws in the design of ALLHAT that call into question the validity of its conclusions. The authors argue that by encouraging use of angiotensin-converting-enzyme inhibitors and calcium channel blockers in ways that are not the standard of care, the trial likely exaggerated the benefits of diuretics in this setting.

    • Lee A Hebert
    • Brad H Rovin
    • Christopher J Hebert
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 3, P: 60-61

  • Acute tubular injury (ATI) significantly contributes to many kidney diseases. Here, the authors identify several immune response and cellular stress plasma proteins linked to ATI severity and acute kidney injury, which may aid in non-invasive ATI assessment.

    • Insa M. Schmidt
    • Aditya L. Surapaneni
    • Sushrut S. Waikar
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-11

  • The coronavirus disease 2019 (COVID-19) pandemic poses important challenges to the care of patients with immune-mediated kidney diseases and to kidney transplant recipients. Here, we discuss the management of immunosuppression for these patients during the pandemic and suggest potential approaches that could be considered in the absence of validated strategies.

    • Andreas Kronbichler
    • Philipp Gauckler
    • Rainer Oberbauer
    Comments & Opinion
    Nature Reviews Nephrology
    Volume: 16, P: 365-367

  • A high-resolution kidney cellular atlas of 51 main cell types, including rare and previously undescribed cell populations, represents a comprehensive benchmark of cellular states, neighbourhoods, outcome-associated signatures and publicly available interactive visualizations.

    • Blue B. Lake
    • Rajasree Menon
    • Sanjay Jain
    ResearchOpen Access
    Nature
    Volume: 619, P: 585-594